Cargando…

Intravitreal ranibizumab as salvage therapy in an extremely low–birth-weight infant with rush type retinopathy of prematurity

We report the effects of intravitreal ranibizumab as salvage therapy in an extremely low–birth-weight (ELBW) infant with rush type retinopathy of prematurity (ROP). This case was a girl of 23 weeks gestational age weighing 480 g at birth. At a postconceptual age of 33 weeks, she presented with zone...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lin, Chun-Ju, Chen, San-Ni, Hwang, Jiunn-Feng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2012
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3574516/ https://www.ncbi.nlm.nih.gov/pubmed/23440056 http://dx.doi.org/10.4103/0974-620X.106103

Ejemplares similares

Intravitreal Ranibizumab for Aggressive Posterior Retinopathy of Prematurity
por: Li, Xiu-Juan, et al.
Publicado: (2016)

Combination of Intravitreal Ranibizumab and Laser Photocoagulation for Aggressive Posterior Retinopathy of Prematurity
por: Mota, Ágata, et al.
Publicado: (2012)

Risk of recurrence of retinopathy of prematurity after initial intravitreal ranibizumab therapy
por: Chan, Joyce J. T., et al.
Publicado: (2016)

Intravitreal ranibizumab for retinopathy of prematurity: The ocular and systemic safety profile query
por: Al Kalbani, Khulood, et al.
Publicado: (2023)

Intravitreal ranibizumab as a primary or a combined treatment for severe retinopathy of prematurity
por: Arámbulo, Odalis, et al.
Publicado: (2015)

Combination therapy of intravitreal ranibizumab and laser photocoagulation for aggressive posterior retinopathy of prematurity
por: Dudani, Ajay I, et al.
Publicado: (2022)

Combined intravitreal ranibizumab and zone I sparing laser ablation in infants with posterior zone I retinopathy of prematurity
por: Parchand, Swapnil M, et al.
Publicado: (2021)

Incidence and risk factors for retinopathy of prematurity in premature, extremely low birth weight and extremely low gestational age infants
por: Yucel, Ozlem Eski, et al.
Publicado: (2022)

Asymmetric Outcomes of Type 1 Retinopathy of Prematurity after Bilateral Intravitreal Ranibizumab Treatment
por: Huang, Qiujing, et al.
Publicado: (2017)

The Incidence and Risk Factors of Severe Retinopathy of Prematurity in Extremely Low Birth Weight Infants in Turkey
por: Celebi, Ali Riza Cenk, et al.
Publicado: (2014)

Intravitreal ranibizumab monotherapy to treat retinopathy of prematurity zone II, stage 3 with plus disease
por: Menke, Marcel N, et al.
Publicado: (2015)

Combination of Intravitreal Injection of Ranibizumab and Photocoagulation for the Treatment of Aggressive Posterior Retinopathy of Prematurity with Vitreous Hemorrhage
por: Xu, Yu, et al.
Publicado: (2016)

Outcomes and prognostic factors for aggressive posterior retinopathy of prematurity following initial treatment with intravitreal ranibizumab
por: Tong, Qizhe, et al.
Publicado: (2018)

Outcomes of early versus deferred laser after intravitreal ranibizumab in aggressive posterior retinopathy of prematurity
por: Gangwe, Anil Babanrao, et al.
Publicado: (2021)

Structural and refractive outcomes of intravitreal ranibizumab followed by laser photocoagulation for type 1 retinopathy of prematurity
por: Hoppe, Charis, et al.
Publicado: (2022)

Rate and Treatment of Retinopathy of Prematurity in Extremely Low Birth Weight Infants with Gestational Age ≤28 Weeks in Eastern China
por: Zhang, Meng, et al.
Publicado: (2020)

Incidence of Retinopathy of Prematurity in Extremely Premature Infants
por: Şahin, Alparslan, et al.
Publicado: (2014)

Screening Retinopathy of Prematurity in Extremely Low Birth Weight Infants in China and the Need for Earlier Screening Times
por: Wang, Jianxun, et al.
Publicado: (2016)

Effect of intravitreal bevacizumab for retinopathy of prematurity on weight gain
por: Obata, Shumpei, et al.
Publicado: (2021)

COMPARISON OF INTRAVITREAL INJECTION OF RANIBIZUMAB VERSUS LASER THERAPY FOR ZONE II TREATMENT-REQUIRING RETINOPATHY OF PREMATURITY
por: Zhang, Guoming, et al.
Publicado: (2017)

Serum Vascular Endothelial Growth Factor Levels before and after Intravitreous Ranibizumab Injection for Retinopathy of Prematurity
por: Chen, Xuting, et al.
Publicado: (2019)

Fluorescein Angiographic Findings of Peripheral Retinal Vasculature after Intravitreal Conbercept versus Ranibizumab for Retinopathy of Prematurity
por: Jin, Enzhong, et al.
Publicado: (2019)

Treatment of Radiation Retinopathy with Intravitreal Injection of Ranibizumab (Lucentis(®))
por: Horowitz, Soraya Alessandra, et al.
Publicado: (2020)

The Severity of Retinopathy in the Extremely Premature Infants
por: Trivli, Alexandra, et al.
Publicado: (2017)

Refractive and Biometric Outcomes in Patients with Retinopathy of Prematurity Treated with Intravitreal Injection of Ranibizumab as Compared with Bevacizumab: A Clinical Study of Correction at Three Years of Age
por: Chen, Yen-Chih, et al.
Publicado: (2018)

Intravitreal Injection of Bevacizumab for Retinopathy of Prematurity in an Infant with Peters Anomaly
por: Minami, Tsuyoshi, et al.
Publicado: (2014)

Aggressive posterior retinopathy of prematurity in infants ≥1500 g birth weight
por: Sanghi, Gaurav, et al.
Publicado: (2014)

Sildenafil and Retinopathy of Prematurity Risk in Very Low Birth Weight Infants
por: Samiee-Zafarghandy, Samira, et al.
Publicado: (2015)

Comparison of OCT angiography in children with a history of intravitreal injection of ranibizumab versus laser photocoagulation for retinopathy of prematurity
por: Zhao, Jinfeng, et al.
Publicado: (2020)

Corrigendum to “The Severity of Retinopathy in the Extremely Premature Infants”
por: Trivli, Alexandra, et al.
Publicado: (2017)

Evaluation of retinal vascularization in retinopathy of prematurity regressed after intravitreal ranibizumab monotherapy or without treatment based on fluorescein angiography
por: Wu, Lei, et al.
Publicado: (2023)

Effect of ranibizumab on retinopathy of prematurity: A meta-analysis
por: Wang, Zhibin, et al.
Publicado: (2022)

Treatment of Intravitreal Ranibizumab Resistant Radiation Retinopathy with Intravitreal Dexamethasone Implant: A Case Report
por: Sabaner, Mehmet Cem, et al.
Publicado: (2022)

Retinopathy of Prematurity among Very-Low-Birth-Weight Infants in Korea: Incidence, Treatment, and Risk Factors
por: Hwang, Jong Hee, et al.
Publicado: (2015)

Ranibizumab Population Pharmacokinetics and Free VEGF Pharmacodynamics in Preterm Infants With Retinopathy of Prematurity in the RAINBOW Trial
por: Fidler, Matthew, et al.
Publicado: (2020)

Survival rate dependent variations in retinopathy of prematurity treatment rates in very low birth weight infants
por: Park, Jae Hyun, et al.
Publicado: (2020)

Inhalation Anesthesia with Sevoflurane during Intravitreal Bevacizumab Injection in Infants with Retinopathy of Prematurity
por: Tokgöz, Orhan, et al.
Publicado: (2013)

Maximum Vasoactive-Inotropic Score and Mortality in Extremely Premature, Extremely Low Birth Weight Infants
por: Aziz, Khyzer B., et al.
Publicado: (2021)

Transcutaneous CO(2) Monitoring in Extremely Low Birth Weight Premature Infants
por: Borenstein-Levin, Liron, et al.
Publicado: (2023)

Evidence to date: ranibizumab and its potential in the treatment of retinopathy of prematurity
por: Patel, Samir N, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_hqjas715pademmuj0ban32t1fo